Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer

The OLCSG1406 study protocol

Research output: Contribution to journalArticle

Abstract

Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalActa Medica Okayama
Volume72
Issue number3
Publication statusPublished - Jan 1 2018

Fingerprint

Chemotherapy
Furosemide
Mannitol
Non-Small Cell Lung Carcinoma
Hydration
Cisplatin
Toxicity
Diuresis
Cells
Kidney
Drug Therapy
Carboplatin
Outpatients

Keywords

  • Cisplatin
  • Furosemide
  • Hydration
  • Lung cancer
  • Mannitol
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{f9beefd6dfa0453f96ddbdbf6b9d1a40,
title = "Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol",
abstract = "Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.",
keywords = "Cisplatin, Furosemide, Hydration, Lung cancer, Mannitol, Non-small cell lung cancer",
author = "Go Makimoto and Eiki Ichihara and Katsuyuki Hotta and Kiichiro Ninomiya and Isao Oze and Daisuke Minami and Takashi Ninomiya and Toshio Kubo and Kadoaki Oohashi and Masahiro Tabata and Yoshinobu Maeda and Katsuyuki Kiura",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "319--323",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer

T2 - The OLCSG1406 study protocol

AU - Makimoto, Go

AU - Ichihara, Eiki

AU - Hotta, Katsuyuki

AU - Ninomiya, Kiichiro

AU - Oze, Isao

AU - Minami, Daisuke

AU - Ninomiya, Takashi

AU - Kubo, Toshio

AU - Oohashi, Kadoaki

AU - Tabata, Masahiro

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.

AB - Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.

KW - Cisplatin

KW - Furosemide

KW - Hydration

KW - Lung cancer

KW - Mannitol

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85048880341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048880341&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 319

EP - 323

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -